Phase III results show rituximab excels against pediatric Burkitt lymphoma
Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated ...
Jun 4, 2020